Micheletti J Morgan, Brink Matthew, Brubaker Jacob W, Ristvedt Deborah, Sarkisian Steven R
From Berkeley Eye Center, Houston, Texas (Micheletti); Matthew Brink LLC, Palm Beach Gardens, Florida (Brink); Sacramento Eye Consultants, Sacramento, California (Brubaker); Vance Thompson Vision, Sioux Falls, South Dakota (Ristvedt); Oklahoma Eye Surgeons, Oklahoma City, Oklahoma (Sarkisian).
J Cataract Refract Surg. 2024 Dec 1;50(12):1284-1290. doi: 10.1097/j.jcrs.0000000000001537.
One of the most impactful recent developments in the glaucoma community has been the concept of interventional glaucoma. In brief, this paradigm shift involves proactive rather than reactive intervention to address glaucoma earlier in the disease process, including in both standalone and combination-cataract settings. By intervening earlier with minimally invasive surgical, laser, or drug-delivery treatments instead of prolonged topical medications, interventional glaucoma aims to take the burden of medication compliance off the patient. It also allows for standalone surgical interventions rather than letting cataract surgery dictate the glaucoma treatment plan. This interventional mindset has been made possible by the increasing diversity and availability of effective minimally invasive treatment options. With these options as a springboard, it is time to reevaluate and advance the traditional glaucoma treatment paradigm.
青光眼领域最近最具影响力的发展之一是介入性青光眼的概念。简而言之,这种范式转变涉及积极主动而非被动反应的干预,以便在疾病进程中更早地治疗青光眼,包括在单纯性和合并白内障的情况下。通过早期采用微创外科手术、激光或药物递送治疗,而不是长期使用局部药物,介入性青光眼旨在减轻患者的药物依从负担。它还允许进行独立的手术干预,而不是让白内障手术决定青光眼的治疗方案。有效微创治疗选择的日益多样化和可及性使这种介入性思维成为可能。以这些选择为跳板,是时候重新评估并推进传统的青光眼治疗范式了。